Navigation Links
Epoxide hydrolase inhibition and Thiazolidinediones: A therapy for cardiometabolic syndrome
Date:4/23/2013

Scientists at the Medical College of Wisconsin and the University of California at Davis, led by Dr. John Imig and Dr. Bruce Hammock have determined the synergistic actions of inhibiting soluble epoxide hydrolase (sEH) with tAUCB (trans-4-(4-[3-adamantan-1-yl-ureid]-cyclohexyloxy)-benzoic acid) and activating peroxisome proliferator-activator receptorγ (PPARγ) with the thiazolidinedione rosiglitazone on the pathological progression of cardiometabolic syndrome. Cardiometabolic syndrome occurs with obesity and hypertension increasing the risks for cardiovascular disease and causing significant and rapidly progressive kidney disease. The findings, which appear in the December 2012 issue of Experimental Biology and Medicine, demonstrate that sEH inhibition and PPARγ activation in combination had the greatest beneficial effects on the multi-disease features and progression of kidney disease associated with cardiometabolic syndrome.

"Inhibitors of sEH have recently reached a point where their ability to combat cardiovascular and kidney diseases can be determined in humans", states Dr. Imig. "In this study we show that when used in combination with a PPARγ agonist therapy for cardiometabolic syndrome that there is a synergistic effect to decrease cardiovascular risk factors and progressive kidney disease. Another potential positive aspect of this combination therapy is that sEH inhibition has beneficial actions to counteract the edema and congestive heart failure that occurs in patients treated long-term with PPARγagonists."

Future studies would include combinational chemistry approaches to design and synthesize drugs with dual sEH inhibitory and PPARγ agonistic activities. Dr. Hammock states, "these approaches are currently being done by his laboratory and others". He also says "that combining sEH inhibition not just with PPARγ but also with other therapies for cardiovascular, inflammatory, and renal diseases are on the horizon and have therapeutic potential as both drug combinations and dual sEH inhibitors with PPARγ activity for treating cardiometabolic syndrome."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said, " This study by John Imig and Bruce Hammack, performed on spontaneous hypertensive and spontaneous hypertensive obese rat models, suggests that a combined therapy with epoxide hydrolase inhibitors and thiazolidinediones may prove to be efficacious in treatment of the multi-disease characteristics of cardiometabolic syndrome. "


'/>"/>

Contact: John Imig
jdimig@mcw.edu
Society for Experimental Biology and Medicine
Source:Eurekalert

Related medicine news :

1. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
2. Novel test identifies patients most likely to benefit from ALK inhibition therapy
3. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
4. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
5. Palliative radiotherapy for bone metastases in elderly patients improves quality of life
6. Physical Therapy Exercises
7. How “Post Rehab Essentials” Helps People Learn About Post Rehab – V kool
8. Intensity modulated radiotherapy reduces side effects in patients with early breast cancer
9. New radiotherapy approach reduces symptoms of dry mouth in patients with head and neck cancers
10. 2 landmark studies report on success of using image-guided brachytherapy to treat cervical cancer
11. Early cognitive behavioural therapy reduces risk of psychosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology: